Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system

Babiker, Hani M.; McBride, Ali; Newton, Michael; Boehmer, Leigh; Drucker, Adrienne; Gowan, Mollie; Cassagnol, Manouchkathe; Camenisch, Todd D.; Anwer, Faiz; Hollands, James M.

doi:10.1016/j.critrevonc.2018.03.014

Cited by 90 publications

(74 citation statements)

References 130 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[ 35–39 ] While the exact mechanism of cancer drug‐induced cardiotoxicity is not well understood, it is clear that chemotherapies can adversely impact several aspects of cardiac function, including electrophysiology, mitochondrial function, contractility, and viability ( Table 1 ). [ 40–45 ] Changes to these structural and functional components can, in turn, alter the intrinsic ability of CMs to contract and generate active force independent of external load or applied stretch.…”

Section: Cardiotoxic Agents and CM Functionmentioning

confidence: 99%

Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity

Blair

Pruitt

2020

Adv Healthcare Materials

View full text Add to dashboard Cite

Cardiomyocytes are the motor units that drive the contraction and relaxation of the heart. Traditionally, testing of drugs for cardiotoxic effects has relied on primary cardiomyocytes from animal models and focused on short‐term, electrophysiological, and arrhythmogenic effects. However, primary cardiomyocytes present challenges arising from their limited viability in culture, and tissue from animal models suffers from a mismatch in their physiology to that of human heart muscle. Human‐induced pluripotent stem cell‐derived cardiomyocytes (hiPSC‐CMs) can address these challenges. They also offer the potential to study not only electrophysiological effects but also changes in cardiomyocyte contractile and mechanical function in response to cardiotoxic drugs. With growing recognition of the long‐term cardiotoxic effects of some drugs on subcellular structure and function, there is increasing interest in using hiPSC‐CMs for in vitro cardiotoxicity studies. This review provides a brief overview of techniques that can be used to quantify changes in the active force that cardiomyocytes generate and variations in their inherent stiffness in response to cardiotoxic drugs. It concludes by discussing the application of these tools in understanding how cardiotoxic drugs directly impact the mechanobiology of cardiomyocytes and how cardiomyocytes sense and respond to mechanical load at the cellular level.

show abstract

Section: Cardiotoxic Agents and CM Functionmentioning

confidence: 99%

Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity

Blair

Pruitt

2020

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Otros anticuerpos monoclonales (pertuzumab, bevacizumab, etc.) e inhibidores de tirosina quinasas (soranefib, sunitinib, imatinib, lapatinib) también son agentes potencialmente cardiotóxicos por este mismo mecanismo 32 .…”

Section: Daño Tipo II O Toxicidad Cardiovascular Con Mecanismo Similaunclassified

Impacto cardiovascular secundario a la terapia para el control del cáncer

Ríos

Rojo²,

Schuster

et al. 2020

Rev. méd. Chile

View full text Add to dashboard Cite

show abstract

“…However, over the years additional research has led to an increase in the number and types of antineoplastic agents available for use (monoclonal antibodies, immune checkpoint inhibitors, protein kinase inhibitors). Correspondingly, many of these agents have been associated with chemotherapy-related adverse cardiovascular effects [3][4][5][6]. A variety of chemotherapeutic compounds have also been found to induce cardiac alterations in preclinical studies (Table 1).…”

Section: Introductionmentioning

confidence: 99%

Spontaneously occurring cardiovascular lesions in commonly used laboratory animals

Herman

Eldridge

2019

Cardio-Oncology

View full text Add to dashboard Cite

The search for new chemical entities which are clinically effective and do not adversely affect the cardiovascular system is an ongoing objective. In vivo studies designed to detect potential drug-induced cardiovascular toxicity typically utilize both rodent and non-rodent species. An important component of such studies includes the microscopic evaluation of tissues for histopathologic changes. A factor which could potentially complicate this type of evaluation relates to the potential for laboratory animals to develop natural or spontaneous pathological cardiovascular lesions. Some types of these naturally occurring alterations are similar to those induced by chemical compounds and thus could confound accurate interpretation. Accurate morphologic analysis becomes contingent upon the ability to distinguish spontaneous cardiovascular changes from actual drug-induced lesions. A summary of some of the more frequently reported spontaneous cardiovascular alterations in commonly-used laboratory animals is presented below. Special emphasis is given to the spectrum of spontaneous background myocardial pathology that might be encountered during preclinical studies conducted to identify potential cardiotoxic actions of anticancer agents.

show abstract

Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system

Cited by 90 publications

References 130 publications

Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity

Mechanobiology Assays with Applications in Cardiomyocyte Biology and Cardiotoxicity

Impacto cardiovascular secundario a la terapia para el control del cáncer

Spontaneously occurring cardiovascular lesions in commonly used laboratory animals

Contact Info

Product

Resources

About